PropertyValue
?:abstract
  • The earliest evidence from China suggested that COVID-19 patients are even more vulnerable to succumbing from complications in the presence of a multimorbid status, including metabolic syndrome. Due to ongoing metabolic abnormalities, non-alcoholic fatty liver disease (NAFLD) appears to be a potential risk factor for contracting SARS-CoV-2 infection and developing related complications. This is because of the interplay of chronically active inflammatory pathways in NAFLD- and COVID-19-associated acute cytokine storm. The risk of severe disease could also be attributed to compromised liver function as a result of NAFLD. We systematically reviewed current literature to ascertain the relationship between NAFLD and severe COVID-19, independent of obesity, which is considered the major factor risk factor for both NAFLD and COVID-19. We found that NAFLD is a predictor of severe COVID-19, even after adjusting for the presence of obesity (OR 2.358; 95% CI: 1.902–2.923, p < 0.001).
is ?:annotates of
?:creator
?:doi
?:doi
  • 10.1007/s42399-020-00631-3
?:journal
  • SN_Compr_Clin_Med
?:license
  • no-cc
?:pdf_json_files
  • document_parses/pdf_json/561b9709b6f2b2e4c669ce94589885bb6f26211d.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7646222.xml.json
?:pmcid
?:pmid
?:pmid
  • 33173850.0
?:publication_isRelatedTo_Disease
is ?:relation_isRelatedTo_publication of
?:sha_id
?:source
  • Medline; PMC
?:title
  • NAFLD and COVID-19: a Pooled Analysis
?:type
?:year
  • 2020-11-06

Metadata

Anon_0  
expand all